Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 2536 to 2550 of 8786 results

  1. Neurostimulation of lumbar muscles for refractory non-specific chronic low back pain

    In development Reference number: GID-HTG10168 Expected publication date: TBC

  2. Trastuzumab deruxtecan with or without pertuzumab for untreated HER2-positive metastatic breast cancer [ID6548]

    Awaiting development Reference number: GID-TA11723 Expected publication date: TBC

  3. Treprostinil diethanolamine for treating pulmonary arterial hypertension [TSID11772]

    Awaiting development Reference number: GID-TA11123 Expected publication date: TBC

  4. Heart valve disease in adults

    Awaiting development Reference number: GID-QS10101 Expected publication date: TBC

  5. Dabigatran etexilate for the secondary prevention of stroke after an embolic stroke of undetermined source [ID1417]

    Awaiting development Reference number: GID-TA10426 Expected publication date: TBC

  6. Elamipretide for treating Barth syndrome in people of any age [ID6545]

    In development Reference number: GID-TA11719 Expected publication date: TBC

  7. Larotrectinib for treating NTRK fusion-positive advanced solid tumours (MA review of TA630) [ID6292]

    In development Reference number: GID-TA11565 Expected publication date: TBC

  8. Fianlimab with cemiplimab for untreated unresectable advanced melanoma or adjuvant treatment of completely resected high-risk melanoma [ID6721]

    Awaiting development Reference number: GID-TA11929 Expected publication date: TBC

  9. Neuromodulation for chronic pelvic pain

    Topic prioritisation

  10. Transcatheter valve-in-valve implantation for the treatment of Tricuspid valve

    Topic prioritisation

  11. Endovascular Arch Repair

    Topic prioritisation

  12. Endovascular stent insertion for intracranial atherosclerotic disease

    Topic prioritisation

  13. Subcutaneous nivolumab–relatlimab for untreated unresectable or metastatic melanoma in people 12 years and over [TSID 12178]

    Topic prioritisation